New type of price agreement between Amgros and Vertex
The Danish procurement organisation, Amgros and the pharmaceutical company Vertex have entered into a new type of price agreement stating a monthly fixed price on pharmaceutical products for treatment of cystic fibrosis regardless of the Danish hospital's consumption of the products.
Moreover, the agreement comprises all new pharmaceutical products for treatment of cystic fibrosis that may be marketed by Vertex during the contract period. The new price agreement was signed on 1 October 2018 and the agreement is effective for a four-year period with the possibility of extension.
The price agreement diverges from the average framework agreements between Amgros and pharmaceutical companies and Amgros has never before entered into such price agreement with fixed prices regardless consumption of the pharmaceutical products.
You can read more about the agreement here (in Danish)
A prior version of this post was originally published by the same authors in Practical Law – Life Sciences, September 2018 Issue (Thomson Reuters).